Company news

Sarepta Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Sarepta Therapeutics and University of Florida Announce Collaboration to Accelerate the Discovery and Development of Therapies for Rare Genetic Diseases

August 10, 2020

Sarepta Therapeutics Announces Second Quarter 2020 Financial Results and Recent Corporate Developments

August 4, 2020

Sarepta Therapeutics to Announce Second Quarter 2020 Financial Results and Recent Corporate Developments on August 5, 2020

July 28, 2020

Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

July 23, 2020

Sarepta Therapeutics Launches “Rare Lessons” Program to Promote Greater Diversity and Inclusion in the Classroom and Support Awareness of Rare Diseases

July 14, 2020

Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Imlifidase

July 1, 2020

Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer

June 29, 2020

Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45

June 25, 2020

Sarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare Diseases

June 21, 2020

Sarepta Therapeutics Announces Positive Safety and Efficacy Data from the SRP-9001 Micro-Dystrophin Gene Therapy Trial Published in JAMA Neurology

June 14, 2020

Sarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E

June 7, 2020

Sarepta Therapeutics to Share Clinical Update from SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

June 4, 2020

Sarepta Therapeutics to Present at the 2020 RBC Capital Markets Virtual Global Healthcare Conference

May 11, 2020

Sarepta Therapeutics and Dyno Therapeutics Announce Agreement to Develop Next-Generation Gene Therapy Vectors for Muscle Diseases

May 10, 2020

Sarepta Therapeutics Announces First Quarter 2020 Financial Results and Recent Corporate Developments

May 5, 2020

Sarepta Therapeutics to Announce First Quarter 2020 Financial Results and Recent Corporate Developments on May 6, 2020

April 28, 2020

Sarepta Therapeutics Announces Research Agreement with U.S. Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as Treatments for COVID-19

April 27, 2020

Sarepta Therapeutics Announces Third Year of Route 79, The Duchenne Scholarship Program

February 26, 2020

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments

February 25, 2020

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments on February 26, 2020

February 18, 2020

Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors

January 12, 2020

Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

January 5, 2020

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 31, 2019

Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001

December 22, 2019

Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing

December 12, 2019

Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53

December 11, 2019

Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies

November 13, 2019

Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments

November 6, 2019

Sarepta Therapeutics to Present at the Credit Suisse 28th Annual Healthcare Conference

November 4, 2019

Sarepta Therapeutics to Announce Third Quarter 2019 Financial Results and Recent Corporate Developments on November 7, 2019

October 23, 2019

Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

October 3, 2019

Sarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

September 24, 2019

← Newer news releases

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 37 decks. Every deck is listed under its year.